Objective: Despite the well-known negative impacts of cancer and anticancer therapies on cognitive performance, little is known about the cognitive compensatory processes of older patients with cancer. This study was designed to investigate the cognitive compensatory processes of older, clinically fit patients with hematologic malignancies undergoing chemotherapy.
task used (Mini-Mental State Examination (MMSE) or Telephone Interview of Cognitive Status), this finding may also support the hypothesis that some patients use cognitive compensatory processes, probably by recruiting additional brain areas, 15 to develop and use additional resources and strategies to perform a task. Clinically, these processes could be reflected, for example, in a feeling of not being able to function as before, a need to increase mental effort for a well-known task, and difficulties to benefit from previous experience.
Although currently impossible to study directly, cognitive compensatory processes can be assessed indirectly through neuroimaging or longitudinal studies comparing cognitive performance of patients and healthy controls. In longitudinal studies, these processes should be studied by assessing the cognitive performance of older cancer patients in novel and non-novel contexts and by assessing psychological factors that may facilitate or inhibit cognitive performance.
Cognitive performance in novel versus non-novel contexts may require different levels of compensatory processes. In a novel context, optimal performance requires memory skills to memorize instructions, as well as executive skills (eg, planning, inhibition, and elaboration strategies) to achieve a goal and reduce interference caused by the novel context itself.
In a non-novel context, optimal performance requires the ability to remember and use previously acquired information through specific strategies, such as category clustering for memory tasks, 16 leading to faster performance, in a less varied, easier manner. 17 Moreover, certain psychological factors may facilitate or inhibit cognitive performance. 18 This modulation reflects the use or nonuse of resources and strategies, known as cognitive compensatory processes, to optimize cognitive functioning.
There are several arguments for collecting novel and non-novel task performances to better understand cognitive compensatory processes. 19 It should be recalled that, compared to a non-novel task, a novel task requires more cognitive efforts. This is certainly the case when a subject is exposed for the first time to a neuropsychological task. When a subject is re-exposed to this task, he may benefit from his previous experience. This benefit is called a "test-retest" effect.
Assessing to what extent a person may benefit of such effect may inform about cognitive compensatory processes.
The aim of this study was to investigate the existence of altered cognitive compensatory processes among older, clinically fit patients with hematologic malignancies undergoing chemotherapy through a longitudinal cohort design. Patients and healthy controls, matched for age, sex, and educational level, had their cognitive performance tested twice, in novel and non-novel contexts. The first exposure of a subject to a cognitive task is considered a good proxy for exposure to a novel context. A second exposure, 1 month later, of the same subject to the same cognitive task is considered a good proxy for exposure to a nonnovel context. Influences of psychological factors, including motivation, psychological distress, and perceived cognitive performance, as potential inhibitors or facilitators of cognitive performance were assessed for both contexts. In this way, cognitive performance and its association with the chosen psychological factors were assessed longitudinally.
Beside the a priori assumption that cancer and related treatments may impair the cognitive performance of older patients, 2 hypotheses regarding the cognitive functioning of older, clinically fit patients were made to investigate cognitive compensatory processes. First, we hypothesized that, contrary to healthy controls, patients would not demonstrate improvement in cognitive performance over time (a practice effect), due to their reduced ability to use cognitive compensatory processes. Second, considering a potential floor effect related to age, cancer, and related treatments, we hypothesized that no association between patients' cognitive performance, motivation to undertake a cognitive task, psychological distress, and perceived cognitive performance would be found in a novel context, reflecting the important cognitive load required to perform a novel task and related difficulties to benefit from psychological facilitator factors. We hypothesized that, in a non-novel context, an association would be found between patients' cognitive performance and these psychological factors, reflecting the reduced cognitive load required to perform a non-novel task.
2 | METHODS
| Patients and setting
This study was conducted in 6 Belgian hospitals and was approved by the local ethics committees. 22 and a shortened version of the FCSR-IR were used to assess working and short-term memory. During the first test, digits were verbally presented to participants at a rate of 1 per second. Participants were asked to repeat digits in the same order for the forward digit span or reverse order for the backward digit span. In the current study, the number of correct trials was used. During the second test consisting of a controlled learning procedure developed by Grober and Buschke, 23 participants were presented with a list of 16 written words. They were asked to associate each word with a given category cue to memorize these words (immediate recall). Thereafter, participants were invited to observe a 20-second distractor period (count back) to prevent rehearsal. Subsequently, free recall and cued recall were assessed. This procedure was repeated after a 20-second distractor period. An alternate form was used at the second assessment. Because first and second free recalls were highly correlated, only the immediate and the second free recalls were used in this study.
The TMT A and B 24 were used to assess processing speed and executive function. TMT A requires to connect 25 encircled numbers as quickly as possible. TMT B requires to alternate consecutive sequences of numbered and lettered circles. Shorter times to completion (in seconds) indicated better performance. The number of errors was also recorded. Regarding part B, as we decided to consider globally cognitive performance, it was decided to take into account both perseverative and normal errors. Because TMT A and B were highly correlated, only results of TMT B were used in this study. On the basis of these 3 tools, we calculated a global cognitive composite z-score consisting of a mean of 5 z-scores.
: 
| Psychological characteristics

Motivation
After completing perceived cognitive performance and before completing objective neuropsychological tasks, patients and healthy controls were asked to report their level of motivation to undertake these tasks on a 100-mm visual analogue scale, ranging from "not at all" to "a lot."
This sequence has been chosen to fit with the objectives of this study.
Perceived cognitive performance
The FACT-Cog (Functional Assessment of Cancer Therapy-Cognitive were used in this study to calculate a global composite perceived cognitive performance z-score (PCPS), which consists of a mean of these 2 variables. A higher PCPS indicates higher perceived cognitive ability.
Psychological distress
The Hospital Anxiety and Depression Scale 27 was used to assess the psychological distress of patients and healthy controls (total score ranged from 0 to 42, higher score indicated higher psychological distress).
| Statistical analysis
Initially, a descriptive analysis of the 2 groups was prepared. Intergroup and intragroup comparisons of cognitive performance and psychological characteristics were computed by using nonparametric tests, as appropriate (Mann-Whitney or Wilcoxon tests). Univariate relationships between groups' cognitive performance and psychological factors were evaluated by using nonparametric tests (Spearman correlations).
Group-by-time effects were analyzed by using a two-way repeated measures multivariate analysis of variance. Finally, backward stepwise linear regression models were computed to assess relationships between psychological factors and cognitive performance for each group in novel and non-novel contexts. All psychological variables with univariate P values ≤0.05 were entered into the model. All tests were two-tailed, and alpha was set at 0.05. Analyses were performed with SPSS software (version 23.0 for Windows; SPSS, Chicago, Illinois).
3 | RESULTS
| Subjects
Among 293 eligible inpatients, 98 refused to participate in the study.
Twenty patients withdrew during the first assessment. In addition, 51
patients did not complete the neuropsychological assessment in the novel context and were excluded from the study. Three patients died Table 2 displays the cognitive and psychological characteristics of participants in novel and non-novel contexts. For cognitive performance, a group effect was found, but no time or group-by-time effect was found. Group effects were found regarding psychological characteristics (perceived cognitive performance, motivation, and psychological distress). A time effect was found for perceived cognitive performance. Finally, a group-by-time effect was found for perceived cognitive performance. Table 3 
| DISCUSSION
To our knowledge, this longitudinal cohort study is the first designed to investigate cognitive compensatory processes of older, clinically fit patients with hematologic malignancies undergoing chemotherapy, through the cognitive performance and associated psychological factors in novel and non-novel contexts. As expected in our hypothesis in the light of available studies about hematologic malignancies, 28 healthy controls performed more optimally than patients in both contexts. The findings did not confirm our first hypothesis that patients would not improve their cognitive performance over time compared to healthy controls. Indeed, no practice effect was found for healthy controls or for patients. Our findings did confirm our second hypothesis that there would be an association between patients' cognitive performance and psychological factors in the non-novel context. A significant positive association was found between the cognitive performance of healthy controls and motivation in both contexts, whereas no significant association was found for patients in the novel context.
In the non-novel context, however, a significant positive association between cognitive performance and motivation and a significant negative association between cognitive performance and psychological distress were found.
Why the results found in patients are not similar to those found in healthy controls? At a cognitive level, our results reinforce the idea that older, clinically fit patients with hematologic malignancies undergoing chemotherapy not only perform less optimally in both novel and non-novel contexts but also (1) do not improve in performance over time (healthy controls did not improve, either) and (2) do not benefit from motivation in a novel context, although low motivation and high psychological distress may decrease performance in a non-novel context. Taken together, these findings suggest that such patients have difficulty in using and/or developing additional resources to compensate for potentially altered cognitive performance due to cancer, anticancer therapy, and their psychological consequences. In other words, for these patients, it is easier to compensate for altered cognitive performance in a non-novel context, in the presence of a high motivation and a low psychological distress level, to complete cognitive tasks. It should be underlined at this level that patients have a significant higher level of psychological distress compared to healthy controls at the 2 assessment points although there is no difference in the evolution over time of psychological distress between the 2 assessments both for patients and for healthy controls.
Previous studies have emphasized cognitive changes related to cancer and chemotherapy among older patients with cancer. To our knowledge, however, this is the first study showing differences between older, clinically fit patients with hematologic malignancies undergoing chemotherapy and matched healthy controls in terms of cognitive compensatory processes in both novel and non-novel contexts. Abbreviation: Std, standard deviation; NA, not applicable. No significant difference was found between patients and healthy controls regarding age (P = 0.842), gender (Chi-squared(1) = 0; P = 1.000), and education (Chi-squared(2) = 0; P = 1.000).
TABLE 2
Cognitive performances and psychological characteristics of included patients undergoing chemotherapy and matched healthy controls in novel and non-novel contexts Correlations between cognitive performances and psychological characteristics of included patients undergoing chemotherapy and matched healthy controls in novel and non-novel contexts 
| CONCLUSION
In conclusion, the results of this study indicate that older, clinically fit patients with hematological malignancies undergoing chemotherapy are at risk for altered cognitive compensatory processes in novel and non-novel contexts, suggesting that these processes should be addressed in cancer care. Although these results improve understanding of patients' cognitive compensatory processes, future studies should identify underlying mechanisms of such processes, to optimize potential revalidation interventions. Future studies should investigate the capacity of other physical, psychological, and social factors, such as physical exercise, perceived cognitive performance, and social support, to influence cognitive compensatory processes. Studies should also investigate the effects of altered cognitive compensatory processes on medical decision making, treatment compliance, daily functioning, and general QOL of patients. As to our knowledge, there are no other studies assessing cognitive compensatory processes in an older cancer patient population; the results of this study should of course be further studied. Finally, revalidation interventions that account for psychological factors, such as motivation and perceived cognitive performance, should be developed and tested to support the cognitive compensatory mechanisms of older patients with cancer.
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